Latest Regulatory Milestones News

Maritana Minerals has secured key regulatory approvals and is progressing critical non-process infrastructure at its Black Swan Processing Hub, keeping the project on track for first gold production in the second half of 2027.

Acrow Limited has secured Phase 1 clearance from the ACCC for its AusGroup Industrial Services acquisition, removing a key regulatory hurdle and setting the stage for completion by the end of August.

Starpharma has successfully completed a $32 million entitlement offer, nearly fully subscribed, to fund its DEP® HER2-Lutetium Phase 1 trial and further develop its oncology pipeline.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

Sky Metals releases a Pre-Feasibility Study confirming Tallebung's robust economics with a 7.3-year mine life, strong cashflows, and rapid capital payback, targeting mid-2028 production.

Flynn Gold is kicking off a 2,500m drilling campaign at its Brilliant Prospect in northeast Tasmania, aiming to convert promising trench assay results into a formal Mineral Resource and fast-track project development.

GoldArc Resources has cleared the last regulatory hurdle for its Mt Stirling gold project, enabling development to proceed under a 50/50 profit-share partnership with BML Ventures.

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.

Flynn Gold has inked a non-binding Ore Purchase Agreement with Kaiser Reef's Henty Gold Mine, opening a potential low-capital route to production for its Golden Ridge project in Tasmania.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.

CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.